Cogent Biosciences, Inc. COGT
27.81 USD -0.04 (-0.14%)
Regular-session close
27.81 0.00 0.00%
After hours · Nov 18, 4:54 PM ET
27.74 Day range 28.77
26.36 52-week range 43.73
- YTD
- -21.71%
- 1 year
- -16.74%
News
seekingalpha.com Cogent Biosciences, Inc. (COGT) Presents at UBS Global Biopharma Conference 2026 Transcript Cogent Biosciences, Inc. (COGT) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $56 HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $55 to $56.
globenewswire.com Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference WALTHAM, Mass. and BOULDER, Colo.
benzinga.com If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 19.53% on an annualized basis producing an average annual return of 30.65%. Currently, Cogent Biosciences has a…
defenseworld.net Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Has Consensus Price Target of $51.56 Cogent Biosciences, Inc. (NASDAQ: COGT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat…
globenewswire.com Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM
seekingalpha.com Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging a single precision molecule for multi-market entry. Positive pivotal data in GIST, NonAdvSM, and…
defenseworld.net Deutsche Bank AG Takes $10.32 Million Position in Cogent Biosciences, Inc. $COGT Deutsche Bank AG acquired a new stake in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The…
defenseworld.net Handelsbanken Fonder AB Purchases New Stake in Cogent Biosciences, Inc. $COGT Handelsbanken Fonder AB acquired a new position in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) during the second quarter, according to the company in its most recent filing with the Securities…
zacks.com Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions…
globenewswire.com Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June…
globenewswire.com Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated…
seekingalpha.com Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal indications with strong clinical data. COGT holds $866.4 million in cash,…
globenewswire.com Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -
globenewswire.com Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria –
globenewswire.com Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16. 5 months versus 9. 2 months (HR=0.…
globenewswire.com Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30,…
globenewswire.com Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference WALTHAM, Mass. and BOULDER, Colo.
globenewswire.com Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress WALTHAM, Mass. and BOULDER, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined…
globenewswire.com Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral…
globenewswire.com Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting WALTHAM, Mass. and BOULDER, Colo.
